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Optimal MSA After PES
1270rug-eluting stents (DES) have dramatically decreased
n-stent restenosis (ISR) compared with bare-metal
tents (BMS) (1,2). However, previous reports indicate
hat stent underexpansion measured by intravascular
ltrasound (IVUS) remains a strong predictor for mid-
erm sirolimus-eluting stent (SES) patency whether pa-
ency is defined by angiography or IVUS criteria (3–5).
See page 1276
nce intimal hyperplasia is suppressed by the drug, stent
nderexpansion as a cause of restenosis appears to be
agnified. To address this issue in paclitaxel-eluting stents
PES), we have used data from the major TAXUS Express
nd TAXUS Liberté trials, each of which had an IVUS
ubstudy (2,6–9). In this report we evaluate the IVUS
arameters that best predicted 9-month follow-up PES pa-
tency defined angiographically.
Methods
Patient population and protocol.
The TAXUS IV, V, and VI trials,
were prospective, double-blind,
BMS-controlled trials in which
patients with a single de novo
native coronary artery lesion were
randomly assigned to treatment
with a PES or an otherwise iden-
tical BMS (both Boston Scien-
tific, Natick, Massachusetts)
(2,6,7). The TAXUS IV and V
studies used the TAXUS Express
stent with the paclitaxel slow-
release (commercially available)
formulation; whereas the TAXUS
I study used the TAXUS Express stent with the moderate-
elease (not commercially available) formulation. TAXUS
TLAS WH (Workhorse), LL (Long Lesion), and DS
Direct Stent) were prospective, single-arm studies comparing
he new generation, thin-strut TAXUS Liberté stent (Boston
cientific), versus TAXUS Express historical control subjects
rom the TAXUS IV and V studies (8,9). Both stents,
AXUS Express SR and TAXUS Liberté, have identical
olymer coating and paclitaxel slow release formulation. Of the
,184 patients enrolled in the 6 trials, 1,580 patients (1,098
ES and 482 BMS) were enrolled in IVUS substudies and
ere included in the current analyses; clinical sites were
elected based on their IVUS experience, volume, and willing-
ess to enroll all of their patients in the IVUS substudy. IVUS
ubstudy patients within each trial were enrolled until the
re-specified numbers were obtained. All pre-specified IVUS
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
SR  in-stent restenosis
VUS  intravascular
ltrasound
LA  minimal lumen area
SA  minimum stent area
ES  paclitaxel-eluting
tent(s)
OC  receiver-operator
haracteristic
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularizationubstudy patients were scheduled for follow-up angiography gnd IVUS at 9 months. The IVUS substudy data from these
rials were analyzed at a single core laboratory (MedStar
esearch Institute, Washington Hospital Center, Washing-
on, DC) (10), and the angiographic studies were analyzed at
single core laboratory (Brigham and Women’s Hospital,
oston, Massachusetts) (9).
ngiographic analysis. Two or more angiographic projec-
ions of the stenosis after intracoronary nitroglycerin were
cquired with repetition of identical angiographic projec-
ions of the lesion at the time of follow-up angiography.
ith the contrast-filled injection catheter as the calibration
ource, quantitative coronary angiographic analysis was
erformed using a validated automated edge-detection al-
orithm (CMS, Medis, Neunen, the Netherlands) by a
echnician who was unaware of the clinical or IVUS
ndings and who was blinded to the treatment arm.
ignificant angiographic ISR was defined as % diameter
tenosis 50%.
VUS protocol and analysis. IVUS imaging was performed
fter intracoronary administration of 0.1 to 0.2 mg nitro-
lycerin using motorized pullback (0.5 mm/s) and contem-
orary, commercial scanners. Images were recorded contin-
ously throughout the stent and at least 5 mm reference
egments distal and proximal to the stent. Images were
ecorded onto s-VHS videotape or onto digital media for
ffline analysis at a single, independent core laboratory by a
echnician who was unaware of treatment assignment or
atient clinical outcomes. With the use of computerized
lanimetry (TapeMeasure, Indec Systems, Mountain View,
alifornia), stent and lumen borders were manually traced
very 1 mm. Post-intervention minimum stent area (MSA)
as defined as the smallest stent area within the length of
he stent.
tatistical analysis. Individual patient data were integrated
rom the 3 TAXUS Express trials (TAXUS IV, TAXUS V
e novo, and TAXUS VI) into 1 common database repre-
enting outcomes across 2 paclitaxel release formulations
slow release and moderate release). For binary data, homo-
eneity of the odds ratios across the 3 TAXUS Express
tudies was assessed with the Breslow-Day test, which tests
he null hypothesis that the odds ratios of the treatment
ffect of PES over BMS across studies are equal. If the
value was more than 0.05, then a treatment effect was
omogeneous across studies. Indeed, the p value of the
reslow-Day tests in theses trials was 0.37, indicating that
ooling of these TAXUS trials was justified. Furthermore,
he stent type effect of TAXUS Express versus TAXUS
iberté was not statistically significant for ISR, and
AXUS ATLAS studies were poolable as well. Categorical
ariables were summarized as frequencies and percentages
nd were compared between groups using chi-square statis-
ics or Fisher exact test, as appropriate. Continuous variables
ere presented as mean  1 SD and compared between
roups using 2-tailed, unpaired t tests or, if parameters were
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1271ot normally distributed per Kolmogorov-Smirnov test,
hen using the Wilcoxon 2-sample test. Differences were
onsidered to be statistically significant when the p value
as 0.05. Multivariate analysis was used to determine
redictors of angiographic ISR. All clinical, angiographic,
nd IVUS covariates listed in Table 2 were modeled
nivariately for each outcome and multivariately using a
tepwise logistic regression. A goodness-of-fit test (Hosmer
nd Lemeshow, a global model fitting) was used to evaluate
he fit of the model; the p value was 0.5 indicating a good
t of the model (little difference between the observed value
nd the expected values). Statistical significance of the
ultivariate analysis was set at a value of p  0.05.
eceiver-operator characteristic (ROC) analysis was used to
easure the ability of post-intervention MSA to discrimi-
ate between those subjects with and without 9-month
ngiographic ISR. The ROC curves plot the probability of
etecting true positive fraction (sensitivity) against false
Table 1. Baseline Clinical and Angiographic Findings and
Procedural Details
PES
(n  1,098)
BMS
(n  482) p Value
Age, yrs 62.3 10.7 62.6 10.5 0.57
Women 312 (28) 148 (31) 0.36
Diabetes 283 (26) 137 (28) 0.27
Hypertension 763 (70) 324 (67) 0.37
Hyperlipidemia 802 (73) 334 (69) 0.13
Smoking 259 (29) 99 (21) 0.001
Prior myocardial infarction 341 (31) 153 (32) 0.79
Unstable angina 382 (35) 149 (31) 0.13
Ejection fraction, % 55.8 9.8 56.9 10.5 0.14
Vessel
Left anterior descending 465 (42) 209 (43) 0.71
Left circumﬂex 294 (27) 127 (26) 0.86
Right 336 (31) 143 (30) 0.71
Pre-intervention angiographic ﬁndings
Type B2/C lesion 803 (73) 353 (74) 0.85
Lesion length, mm 16.4 8.1 16.4 8.8 0.94
Reference vessel diameter, mm 2.77 0.48 2.75 0.53 0.33
Minimal lumen diameter, mm 0.9 0.4 0.9 0.4 0.82
Diameter stenosis, % 68.8 11.1 68.3 11 0.42
Post-intervention angiographic ﬁndings
In-stent minimal lumen diameter, mm 2.63 0.45 2.64 0.46 0.94
In-stent diameter stenosis, % 6.0 9.6 4.1 10.9 0.01
Procedural details
Maximum inﬂation pressure, atm 15.3 3.4 14.4 4.2 0.0001
Stent length, mm 25.2 11.1 26.6 12.0 0.035
Stent/lesion length ratio 1.7 0.7 1.8 0.9 0.0013
Stent/artery ratio 1.15 0.15 1.15 0.17 0.48
Post-dilation performed, % 66.3% 71.5% 0.0424
Values are mean SD or n (%).
BMS bare-metal stent(s); PES paclitaxel-eluting stent(s).ositive fraction (1-specificity) of 9-month ISR over thentire range of observed MSAs. In general: 1) ROC  0.5
uggests no discrimination; 2) 0.7  ROC  0.8 is
onsidered acceptable discrimination; 3) 0.8  ROC  0.9
s considered excellent discrimination; and 4) ROC  0.9 is
onsidered outstanding discrimination. However, to deter-
ine the IVUS MSA cutoff point value for each treatment
roup that best predicted 9-month angiographic ISR or
tent patency, the cross point of sensitivity and specificity
urves was used. No adjustments for differences between
MS and PES were used.
esults
aseline clinical and lesion characteristics comparing PES
nd BMS treatment groups are shown in Table 1. In
ddition, while there were no differences in age, sex, and
oronary risk factors between patients with and without
VUS in the combined TAXUS IV, V, and VI and TAXUS
TLAS Workhorse, Long Lesion, and Direct Stent
rials, lesions in the IVUS substudy had larger baseline
eference vessel diameter (2.77  0.50 mm vs. 2.66 
.54 mm, p  0.0001), longer lesion length (16.4  8.3
m vs. 15.7  7.9 mm, p  0.0058), greater % diameter
tenosis (68.7  11.1% vs. 67.3  11.3%, p  0.0001), and
ore frequent type B2/C lesion types (modified American
ollege of Cardiology/American Heart Association lesion
lassification, 73.4% vs. 69.1%, p  0.0022) than those not
n the IVUS substudy. Among the PES group in the IVUS
ohort, hyperlipidemia (77% vs. 68%, p  0.0013) and
moking (37% vs. 23%, p  0.001) were more frequent in
he LIBERTÉ subgroup compared with the EXPRESS
ubgroup. The EXPRESS subgroup had a smaller baseline
eference vessel diameter (2.74  0.49 mm vs. 2.80  0.48
m, p  0.034) and a longer lesion length (17.0  8.6 mm
s. 16.0  7.7 mm, p  0.030) compared with the
IBERTÉ subgroup despite less frequent type B2/C lesion
haracteristics (modified American College of Cardiology/
Table 2. Univariate and Multivariate Predictors of ISR in
TAXUS-Treated Patients
Variable Coefficient
Standard
Error
Odds Ratio
(95% CI) p Value
Univariate analysis 0.05
Pre-RVD (mm) 0.9945 0.2455 0.37 (0.23–0.60) 0.0001
Post-intervention
IVUS MSA (mm2)
0.2597 0.0688 0.77 (0.67–0.88) 0.0002
Sex 0.6088 0.2219 1.84 (1.19–2.84) 0.0061
Multiple study
stents Implanted
0.5898 0.2464 1.80 (1.11–2.92) 0.0167
Multivariate analysis
Post-intervention
IVUS MSA (mm2)
0.2597 0.0703 0.77 (0.67–0.89) 0.0002
CI  confidential interval; ISR  in-stent restenosis; IVUS  intravascular ultrasound; MSA minimal stent area; RVD reference vessel diameter.
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1272merican Heart Association lesion classification, 67% vs.
8%, p  0.001).
atient and lesion characteristics and angiographic and IVUS
ndings post-intervention. Baseline clinical and lesion char-
cteristics were similar in both PES- and BMS-treated
roups (Table 1). Post-intervention quantitative coronary
ngiography in-stent diameter stenosis measured 6.0 
.6% in the PES group and 4.1  10.9% in the BMS
roup (p  0.01), and IVUS MSA measured 6.6  2.5
m2 in the PES group and 6.7  2.3 mm2 in the BMS
roup (p  0.92).
ngiographic ﬁndings at 9-month follow-up. At 9 months of
ollow-up, quantitative coronary angiography in-stent min-
mum lumen diameter measured 2.2  0.7 mm in the PES
roup and 1.7  0.7 mm in the BMS group (p  0.001),
nd quantitative coronary angiography in-stent diameter
tenosis measured 20.5  20.0% in the PES group and
8.2  22.2% in the BMS group (p  0.001). Overall, 10%
f patients in the PES group had angiographic ISR com-
ared with 31% of patients in the BMS group (p  0.001).
VUS predictors of 9-month angiographic restenosis. Table 2
hows the univariate predictors (p  0.05) of angiographic
SR after PES implantation. Subsequent multivariate anal-
sis identified the post-intervention IVUS MSA as the only
ndependent predictor of angiographic ISR (odds ratio: 0.77
95% confidence interval: 0.67 to 0.89], p  0.0002). ROC
nalysis was then performed to determine the ability of the
ost-intervention IVUS MSA to discriminate between
ES-treated patients with versus without 9-month angio-
raphic ISR over the entire range of MSA values (Fig. 1).
he c-statistic for PES-treated patients was 0.6382 (close to
cceptable discrimination) (Fig. 1); however, the p value in
he Hosmer and Lemeshow test was 0.5211, indicating that
re-intervention MSA was a faithful discriminator between
atients with and without ISR at 9 months post-stent
mplantation. The single post-intervention MSA value that
est separated patients with 9-month angiographic ISR
rom those with no ISR was 5.7 mm2 (Fig. 1). Using this
ut-point to separate the patient population into subgroups
evealed that the rate of angiographic ISR was 7.2% for
atients with an IVUS MSA5.7 mm2 compared with 14.5%
n patients with an IVUS MSA5.7 mm2 (p 0.0016); and
he positive and negative predictive values were 13.6% and
2.0%, respectively. Comparing the patients with an IVUS
SA 5.7 mm2 with those with an IVUS MSA 5.7
m2: 1) diabetes mellitus was more frequent (29% vs. 23%,
 0.0001); 2) baseline reference vessel diameter was
maller (2.47 0.31 mm vs. 3.04 0.42 mm, p 0.0001);
) baseline minimal lumen diameter was smaller (0.77 
.29 mm vs. 0.97  0.37 mm, 0.0001 for minimal lumen
iameter); and 4) post-intervention minimal lumen diame-
er was smaller (2.34  0.30 vs. 2.90  0.35, p  0.0001).
f note, the results were almost identical when analyzingust the slow-release formulation (MSA of 5.6 mm2); Mowever, there were not enough patients to analyze just the
oderate release formulation.
When a similar analysis was performed for BMS-treated
atients, independent predictors of BMS restenosis in-
luded post-intervention IVUS MSA (odds ratio: 0.77 [95%
onfidence interval: 0.67 to 0.88], p  0.0002) and implan-
ation of multiple BMS (Table 3). The c-statistic for the
Figure 1. Optimal MSA in PES
(A) Sensitivity and speciﬁcity curves for intravascular ultrasound mini-
mum stent area (MSA) predicting angiographic in-stent restenosis (ISR)
in paclitaxel-eluting stent (PES)-treated patients. The single post-
intervention MSA value that best separated patients with 9-month an-
giographic ISR from those with no ISR was 5.7 mm2 in PES-treated pa-
tients. (B) Receiver-operator characteristic analysis of the intravascular
ultrasound MSA for angiographic ISR in PES-treated patients. Receiver-
operator characteristic analysis was performed to determine the ability
of the post-intervention intravascular ultrasound MSA to discriminate
between PES-treated patients with versus without 9-month angio-
graphic ISR over the entire range of MSA values. The c-statistic for PES-
treated patients was 0.6382.SA was 0.6373 (close to acceptable discrimination) (Fig. 2);
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1273owever, the p value of the pre-intervention IVUS MSA in
he Hosmer and Lemeshow test was 0.9033, indicating that
re-intervention MSA was a faithful discriminator between
atients with and without ISR at 9 months post-stent
mplantation. The single MSA value that best separated
atients with 9-month ISR from those with no ISR was 6.4
m2 (Fig. 2); the rate of ISR in patients with an IVUS
SA 6.4 mm2 was 25% compared with 40% in patients
ith an IVUS MSA 6.4 mm2 (p  0.001), and the
ositive and negative predictive values were 40.0% and
5.6%, respectively.
iscussion
he current analysis explored the predictors of angiographic
estenosis after PES implantation and, in particular, the
elationship between angiographic restenosis and baseline
VUS MSA in more than 1,500 patients, more than 1,000
reated with PES and almost 500 treated with BMS.
he importance of stent expansion in the BMS era. IVUS
tudies in the BMS era showed that stents were often
nderexpanded despite adequate angiographic results and
hat post-intervention MSA measured by IVUS predicted
ubsequent target lesion revascularization (TLR) or mid-
erm stent patency (defined as IVUS minimal lumen area
MLA] 4.0 mm2) (3,11,12). Castagna et al. (11) reported
he incidence of stent underexpansion in 1,090 patients with
SR after BMS implantation; in this single-center cohort,
8% of BMS restenosis lesions had an MSA 6.0 mm2,
nd 20% had an MSA 5.0 mm2. Using data from the
RUISE (Can Routine Intravascular Ultrasound Influence
tent Expansion) trial, Morino et al. (12) showed that an
SA of 6.5 mm2 best separated TLR from no TLR at
-month follow-up; the TLR rate was 16.7% in patients
Table 3. Univariate and Multivariate Predictors of ISR in
BMS-Treated Patients
Variable Coefficient
Standard
Error
Odd Ratio
(95% CI) p Value
Univariate analysis 0.05
Multiple stents
implanted
1.4394 0.2397 4.22 (2.64–6.75) 0.0001
Lesion length (mm) 0.0551 0.0121 1.06 (1.03–1.08) 0.0001
Pre-RVD (mm) 0.7807 0.2155 0.46 (0.30–0.70) 0.0003
Post-intervention
IVUS MSA (mm2)
0.2353 0.0643 0.79 (0.70–0.90) 0.0003
Pre-MLD (mm) 1.0638 0.3405 0.35 (0.18–0.67) 0.0018
Diabetes requiring
medication
0.5471 0.2328 1.73 (1.10–2.73) 0.0188
Multivariate analysis
Multiple stents
implanted
1.2784 0.3056 3.59 (1.97–6.54) 0.0001
Post-intervention
IVUS MSA (mm2)
0.2677 0.0709 0.77 (0.67–0.88) 0.0002pBMS bare-metal stent(s); MLDminimal lumen diameter; other abbreviations as in Table 2.ith an MSA of 6.5 mm2 and 5.8% in patients with an
SA of 6.5 mm2 (p  0.0001). This cutoff value was
upported by Sonoda et al. (3) using data from the SIRIUS
SIRolImUS-Eluting Balloon Expandable Stent in the
reatment of Patients With De Novo Native Coronary
rtery Lesions) trial; an MSA of 6.5 mm2 for BMS best
eparated IVUS patency from nonpatency, but with a
Figure 2. Optimal MSA in BMS
(A) Sensitivity and speciﬁcity curves for intravascular ultrasound MSA
predicting angiographic ISR in bare-metal stent (BMS)-treated patients.
The single post-intervention MSA value that best separated patients
with 9-month angiographic ISR from those with no ISR was 6.4 mm2 in
paclitaxel-eluting stent-treated patients. (B) Receiver-operator character-
istic analysis of the intravascular ultrasound MSA for predicting angio-
graphic ISR in BMS-treated patients. Receiver-operator characteristic
analysis was performed to determine the ability of the post-intervention
intravascular ultrasound MSA to discriminate between BMS-treated
patients with versus without 9-month angiographic ISR over the entire
range of MSA values. The c-statistic for BMS-treated patients was
0.6373. Abbreviations as in Figure 1.ositive predictive value of only 56%. This cutoff value was
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1274lso substantiated in the BMS arm of the current analysis in
hich an IVUS MSA of 6.4 mm2 best separated 9-month
ngiographic restenosis from no restenosis, with a negative
redictive value of 75.6%, but a low positive predictive value
f 40.0%. While a post-intervention MSA 6.4 mm2
emonstrated good ability to identify patients with stent
atency at 9 months post-BMS implantation, there was a
imited value of MSA 6.4 mm2 in predicting subsequent
estenosis. This, along with c-statistics of 0.6373, indicates
hat other lesion or patient factors may also significantly
nfluence BMS restenosis at 9 months. Nevertheless, the
ultivariate analysis demonstrated that both MSA and
ultiple stents implantation were significant predictors of
ngiographic ISR.
he importance of stent underexpansion in the DES era. Stent
nderexpansion assessed by IVUS seems to be a stronger
redictor for mid-term stent patency after SES implantation
ompared with BMS implantation (3–5). In the IVUS
ubstudy of the SIRIUS trial, a significant positive correla-
ion was observed between IVUS follow-up MLA and
VUS post-intervention MSA in both the SES and BMS
roups (3); however, the correlation was higher for SES
han for BMS indicating that stent expansion influenced
id-term patency more in SES than BMS. Sonoda et al. (3)
using IVUS MLA end points) and Hong et al. (4) (using
ngiographic restenosis end points) showed that the post-
ntervention MSA that best separated mid-term patency
rom nonpatency after SES implantation was 5.0 to 5.5
m2. The SIRIUS trial enrolled relatively low-risk patients,
hile Hong et al. (4) included both low- and high-risk
atients in their single-center registry. The study by Hong
t al. (4) also reported that a stent length of 40 mm best
eparated angiographic restenosis from no restenosis. When
atients were divided into 4 groups according to the MSA
nd stent length, the angiographic restenosis rates were
.4% (MSA 5.5 mm2, stent length 40 mm), 2.4%
MSA 5.5 mm2, stent length 40 mm), 8.6% (MSA
5.5 mm2, stent length 40 mm), and 17.7% (MSA 5.5
m2, stent length 40 mm). Another IVUS study of 169
esions in 138 patients treated with SES showed that a
ost-intervention MSA of 5.0 mm2 and a stent length of
30 mm were independent predictors for angiographic
estenosis (5).
The current analysis extends these observations to PES-
reated patients. A post-intervention IVUS MSA 5.7 mm2
an predict subsequent PES patency with a negative predictive
alue of 92%. Like SES, PES also decreases intimal hyperpla-
ia compared with BMS, albeit to a lesser extent (13,14). The
ess profound effect of paclitaxel on intimal hyperplasia com-
ared with sirolimus may be one possible explanation for the
omewhat larger MSA that best separated restenosis from
onrestenosis in PES (5.7 mm2) in the current study compared
ith SES in previous studies (5.0 to 5.5 mm2). A slightly larger
SA may be needed to accommodate a little more intimal fyperplasia in PES versus SES just as a much larger MSA is
ecessary to accommodate significantly more intimal hyperpla-
ia in BMS versus DES.
s a DES MSA of 5.0 or 5.7 mm2 large enough in all
ituations? Probably not and for many reasons. First, the
IRIUS and TAXUS trials enrolled relatively low-risk
atients compared with real-world cohorts. Studies have
onsistently showed a relationship between increasing pa-
ient and lesion complexity and increased risk of restenosis.
Second, sensitivity/specificity curve analysis identified a
ingle number for MSA that best separates the subsequent
resence of an event from no event; however, this cutoff was
elected from the MSA values observed only in the current
rials, and, therefore, cannot be generalized. Third, multi-
ariate analysis demonstrated that the post-intervention
SA was a significant predictor of ISR at 9 months, with
dentical risk reduction with a larger MSA for both PES
nd BMS. Also, the ROC analysis showed virtually an
dentical ability of MSA for both PES and BMS to
iscriminate between 9-month ISR and stent patency. In
he current analysis, c-statistics were virtually identical for
ES and BMS, and a c-statistic of 0.64 is better than
hance, less than perfect. The c-statistics in the current
nalysis took all IVUS MSA values into consideration; they
ere not related to any specific cut-point, but to MSA as a
ontinuous variable. Of note, c-statistics were not reported
y Sonoda et al. (3) or Hong et al. (4) in their previous
eports. Conversely, when it comes to individual MSA
alues, the negative or positive predictive values show the
ccuracy of the selected MSA cut-points as “diagnostic”
ests. In the current study, both cut-points are accurate in
redicting stent patency, but the cut-points are not good in
redicting restenosis. If the MSA is larger than the cut-
oint, then the chance of not developing restenosis is high.
f the MSA is less than the cut-point, then restenosis may
r may not occur. In addition, other factors—strut fracture,
onhomogeneous stent-strut distribution, and so on—must
e taken into account. Fourth, in all of the studies cited in
he preceding text as well as in the current analysis, there
as a stepwise relation between the post-intervention MSA
nd the likelihood of restenosis; a post-intervention MSA
arger than the cut-point was associated with a greater
hance of 9-month follow-up patency. Fifth, interventional
ardiologists routinely use the manufacturer-supplied com-
liance charts to target final stent dimensions on the basis of
tent size and inflation pressures. However, a comprehen-
ive IVUS analysis showed that stents—whether BMS or
ES—achieve only 75  10% of predicted minimum stent
iameter and 66  17% of predicted MSA (15).
Finally, if “one size fit all,” theoretically an MSA of 6.5 mm2
ould be achieved by 100% expansion of any 2.5 to 3.0 mm
MS, and an MSA of 5.0 to 5.7 mm2 would be achieved by
00% expansion of any 2.5 to 2.75 mm DES. Thus, manu-
acturers would only have to make one size stent for all vessels
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1275ith reference diameter 2.5 mm, and one size would fit all
ituations. This was not the case in the early SES experience
hen shortages in larger stent sizes lead to the use of under-
ized stents in larger vessels with a high rate of adverse events.
tudy limitations. First, the results obtained are limited to
essel diameters and stent lengths used in the TAXUS IV, V,
nd VI and TAXUS ATLAS Workhorse, Long Lesion, and
irect Stent trials. These trial cohorts may include relatively
ower risk patients in comparison with real-world practice, and
his might limit the use of the suggested MSA cutoff values in
linical practice. Second, this was a post-hoc analysis, and the
omparison between BMS and PES was nonrandomized and
nadjusted. However, the objective of this analysis was to
etermine post-procedural MSA values for PES and BMS
hat best predict ISR at 9 months rather than to compare the
tents. Finally, the definition of ISR is based on a protocol-
riven 9-month angiographic follow-up and may differ from
linically defined restenosis.
onclusions
n the combined IVUS analysis of the TAXUS IV, V, and VI
nd TAXUS ATLAS Workhorse, Long Lesion, and Direct
tent trials, post-intervention MSA measured by IVUS can
redict 9-month follow-up stent patency after both PES and
MS implantation. Thus, post-intervention IVUS may help to
chieve optimal stent expansion after PES or BMS implanta-
ion to reduce underexpansion-related complications such as
arly/late thrombosis and restenosis.
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